Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline May 9, 2024
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting Apr 18, 2024
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings Apr 16, 2024
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients Apr 10, 2024
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments Mar 28, 2024
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program Mar 5, 2024
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers Feb 22, 2024
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers Feb 20, 2024
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments Nov 9, 2023
